Summit Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies and treatments for serious infectious diseases. The company's flagship clinical program centers on ivonescimab, an investigational bispecific antibody that combines immunotherapy via PD-1 blockade with anti-angiogenesis effects, currently in Phase III trials for non-small cell lung cancer (NSCLC) and colorectal cancer. Historically, the company has also developed ridinilazole, an orally administered small molecule antibiotic for Clostridioides difficile infection (CDI). Headquartered in Miami, Florida, Summit Therapeutics operates geographically across the United States and the United Kingdom. The company is focused on advancing its pipeline through clinical development and regulatory approval to address significant unmet medical needs.
